Raymond James added Blueprint Medicines to the firm’s Analyst Current Favorites list. The firm made no change to the Strong Buy rating or $85 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cogent Biosciences initiated with Outperform, $20 target at Baird
- Blueprint Medicines to present new clinical data at 2023 ASCO meeting
- Blueprint Medicines: FDA lifts partial clinical hold on Phase 1/2 VELA trial
- Blueprint Medicines participates in a conference call with JMP Securities
